Skip to content

Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))

Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00969982
Enrollment
238
Registered
2009-09-02
Start date
2009-06-30
Completion date
2013-06-30
Last updated
2014-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion, Induced

Keywords

Pregnancy termination, abortion, medical abortion, 2nd trimester, mifepristone, misoprostol

Brief summary

The primary goal of this study is to determine the clinical advantage of pre-treatment with mifepristone in second trimester misoprostol induction abortion. This will be a randomized controlled double-blinded trial of 120 women in each country comparing misoprostol alone to mifepristone plus misoprostol for second trimester (14-21 weeks' LMP) medical abortion.

Interventions

single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.

DRUGmisoprostol+placebo

placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.

Sponsors

Gynuity Health Projects
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* 14 to 21 weeks gestation, based on menstrual history and clinical exam (with or without ultrasound) * Meet legal criteria to obtain abortion * Present with closed cervical os and no vaginal bleeding * Live fetus at time of presentation for service * Have no contraindications to study procedures, according to provider * Be able to consent to procedure, either by reading consent document or by having consent document read to her * Be willing to follow study procedures

Exclusion criteria

* Known previous transmural uterine incision * Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol * Any contraindications to vaginal delivery, including placenta previa * Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)

Design outcomes

Primary

MeasureTime frame
Rate of successful abortion: defined as complete evacuation using study drug without recourse to any additional intervention.48 hours
Induction-to-abortion interval: defined as time elapsed between administration of the first misoprostol dose until expulsion of the fetus.48 hours

Secondary

MeasureTime frame
Total dose of misoprostol.Assessed at time of complete abortion with study drug alone or when total maximum dose given.
Provision of additional interventions to manage excessive blood lossfrom start of treatment until discharge
Women's acceptability of the assigned methodAssessed at exit interview
Pain experienced by the woman as self-reported.Assessed during exit interview.
Any heavy bleeding, uterine rupture, or infection requiring additional treatmentstart of treatment until discharge

Countries

Moldova, Tunisia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026